

## Antimicrobial resistance pattern of Uro-Pathogens emphasizing non-lactose fermenting gram negative bacilli

Ambreen Fatima<sup>1</sup>, Mehwish Rizvi<sup>2</sup>, Mehwish Sajjad<sup>3</sup>, Hareem Gohar<sup>4</sup>, Wajiha Iffat<sup>5</sup>, Rabia Bushra<sup>6</sup>

### Abstract

**Objective:** To identify various species of non-lactose fermenting gram-negative bacilli involved in urinary tract infections, and to determine their antimicrobial resistance pattern.

**Method:** The retrospective, descriptive, cross-sectional study was conducted from January 1 to April 1, 2022, at the Dow University of Health Sciences, Karachi, and comprised data from the institutional diagnostic laboratory that was related to urine samples regardless of age and gender from January 1, 2020, to December 31, 2021. Data was analysed using SPSS version 25.

**Results:** Of the 103,887 urine samples, 41,280(39.7%) were positive, 51,146(49.2%) showed no bacterial growth, 11,000(10.6%) had non-significant bacterial growth and 461(0.4%) had mixed bacterial growth. Of the positive samples, 18359(44.5%) were positive in 2020, and 22,921(55.5%) in 2021. Gram-negative lactose fermenting bacteria included *Escherichia coli* 23,123(22.3%) and *Klebsiella pneumoniae* 2,993(2.9%), gram-negative non-lactose fermenting bacteria included *Pseudomonas aeruginosa* 1,110(1.07%), and gram-positive bacteria included *Enterococcus* 8,008(7.7%). *Pseudomonas aeruginosa* was most resistant against tobramycin 880(79.3%) and least resistant against piperacillin-tazobactam 146(13%).

**Conclusion:** Piperacillin-tazobactam was highly sensitive drug against non-lactose fermenting uro-pathogens.

**Key Words:** Antimicrobial resistance, Non-lactose fermenting, Gram-negative bacteria, Urinary tract infection.

(JPMA 74: 661; 2024) DOI: <https://doi.org/10.47391/JPMA.9317>

### Introduction

Gram-negative bacilli are common pathogens associated with urinary tract infections (UTIs). These gram-negative bacilli are becoming more resistant to several antibiotics with time.<sup>1</sup> The gram-negative organisms that cause frequent onset of UTIs are mainly *Escherichia (E.) coli* and *Klebsiella (K.) pneumoniae*.<sup>2</sup> UTI is among the most common bacterial infections affecting all age groups. UTI is one of the major public health concerns in terms of illness and financial burden, contributing greatly to healthcare expense. It has been recently estimated in the United States that around 8.6 million healthcare visits were made annually, resulting in serious global economic burden<sup>3</sup>. Prevalence of UTI is affected by multiple factors, such as old age, poor personal hygiene, pregnancy, urinary catheterisation, genitourinary tract abnormalities, and co-morbidities, including diabetes and human

immunodeficiency virus (HIV) infections. Clinically, UTI may present as asymptomatic, acute, chronic, complicated, or uncomplicated, depending upon the type of infectious agent, part of the urinary tract involved, and patient's immune response.<sup>4</sup> Most UTIs are treated empirically based on the culture and sensitivity pattern generated by microbiology laboratories. The spectrum of antimicrobial susceptibility of UTI pathogens varies from time to time and in different geographic areas. Therefore, regular monitoring of the antibiotic susceptibility pattern of these uro-pathogens is required for reduction and eradication of antimicrobial resistance. The antimicrobial resistance against broad-spectrum antibiotics is increasing with every passing day owing to excessive and irrational utilisation, self-medication, mal-drug disposal practices, and genetic proliferation among bacterial species.<sup>5</sup>

UTIs are more common in females than males due to anatomical proximity of urethra to the gut opening.<sup>6</sup> UTI signifies common illnesses confronted in medical practice today, with an expected 150 million UTIs each annum globally. Around 20% of UTIs are documented to be found in males. In healthy women, uncomplicated UTIs have a prevalence of 50/1000/time.<sup>7</sup> Besides, 50% of females experience UTI incidence at least once in their lifetime, and 20-40% females have chronic episodes.<sup>8</sup>

.....  
<sup>1,3</sup>Department of Pathology, Dow International Medical College, Dow University of Health Sciences, <sup>2,5,6</sup>Department of Pharmaceutics, Dow College of Pharmacy, Dow University of Health Sciences, <sup>4</sup>Department of Microbiology, Dow Diagnostic Research and Reference Laboratory, Dow University of Health Sciences, Karachi, Pakistan.

**Correspondence:** Mehwish Rizvi. Email: mahwishkhi@gmail.com

**ORCID ID:** 0000-0003-4115-0382

**Submission complete:** 27-02-2023

**Review began:** 10-04-2023

**Acceptance:** 30-12-2023

**Review end:** 06-12-2023

Most incidents of UTI are triggered by *E. coli*, while *K. pneumoniae*, *Staphylococcus (S.) saprophyticus* and *Proteus* species represent the remaining infections.<sup>2</sup> Susceptibility data from regional microbiological services help in the empirical range of antibiotics for treatment of UTI, though such data is restricted to complex UTIs as uncomplicated UTI samples are hardly sent to the laboratories. The growing prevalence of drug resistance amongst uro-pathogens is considerable for public health interest, requiring continuous antibiotic susceptibility screening for bacteria causing UTI. Additionally, antimicrobial sensitivity for UTI-causing bacteria is documented to change with time and location. Thus, screening for sensitivity is significant for creating up-to-date epidemiological information.<sup>9</sup> The heterogeneous group of proteobacteria, non-lactose-fermenting gram-negative bacteria (NLF-GNB) is distinguished by the failure to ferment carbohydrates for energy production to carry out their essential cellular purposes. In UTIs, NLF-GNBs must not be overlooked as they are essential bacteria from the epidemiological perspective with greater prevalence.<sup>10</sup> These contain, in descending order of occurrence, *Pseudomonas*, *Acinetobacter*, *Burkholderia cepacia* complex (BCC), and *Stenotrophomonas (Xanthomonas) maltophilia*. Additionally, there are *Achromobacter*, *Alcaligenes*, *Brevibacterium*, *Elizabethkingia*, *Flavobacterium*, *Ralstonia* and others. Some less predominant members, for instance *Burkholderia (B.) mallei* and *B. pseudomallei*, acquire significance as bioterrorism representatives.<sup>11</sup> They are very common in cunning infections, impacting harshly immunocompromised and weakened patients aged around 60 years.

The current study was planned to identify various species of NLF-GNB involved in UTIs, and to determine their antimicrobial resistance pattern.

## Materials and Methods

The retrospective, descriptive, cross-sectional study was conducted from January 1 to April 1, 2022, at the Dow University of Health Sciences (DUHS), Karachi, and comprised data from the institutional diagnostic laboratory that was related to urine samples regardless of age and gender from January 1, 2020, to December 31, 2021.

Duplicate samples, catheter specimens, specimens with growth of *Candida* species, data of antibiotic susceptibility patterns of all isolated gram-positive bacteria and lactose-fermenting gram-negative bacteria of other sources, like blood, pus, pleural fluids, etc., were excluded.

After approval from the institutional ethics review committee, midstream urinary specimen was inoculated on Cystine lactose electrolyte deficient (CLED) agar (Oxoid, United Kingdom) by colony count quantitative method using 0.001ml loop by sterile microbiological method. After 18-24 hours of incubation at 37°C oxygen (O<sub>2</sub>) plate was observed for growth, if any. Re-incubations were performed for the plates with no growth after another 24 hours of incubation. Existence of 10<sup>5</sup>CFU/ml was considered significant.

Growth of non-lactose fermenting colonies on MacConkey agar was later identified by colony's morphology, gram staining and various biochemical tests, including catalase test, oxidase reaction, citrate test, sulfur indole motility (SIM) test, triple sugar iron (TSI) test and urease test, while the final confirmation was done by Analytical Profile Index (API 20E and API 20NE (bioMérieux, France), as needed. Antibiotic susceptibility test was done using the Kirby-Bauer disk diffusion test protocol with 0.5 McFarland turbidity standard.<sup>12</sup>

Antimicrobial discs (Oxoid, UK; Bioanalyse, Turkey) included amikacin (AMK; 30µg), gentamicin (CN; 10µg), tobramycin (TOB; 10µg), ampicillin (AMP; 10µg), amoxiclav (AMC; 20/10µg), cefuroxime (CFM; 30µg), ceftriaxone (CRO; 30µg), cefixime (CFM; 5µg), ceftazidime (CAZ; 30µg), piperacillin-tazobactam (TZP; 100/10µg), meropenem (MEM; 10µg), levofloxacin (LEV; 5µg), ciprofloxacin (CIP; 5µg), trimethoprim/sulphamethoxazole (SXT; 1.25/23.75µg). The inverted plates were incubated at 37°C for 16-18 hours. The zone of inhibition was measured by scale and compared with the Clinical and Laboratory Standards Institute (CLSI) guidelines<sup>13</sup>.

Data was analysed using SPSS version 25.

## Results

Of the 103,887 urine samples, 41,280(39.7%) were positive, 51,146(49.2%) showed no bacterial growth, 11,000(10.6%) had non-significant bacterial growth and 461(0.4%) had mixed bacterial growth.

Of the positive samples, 18,359(44.5%) were positive in 2020, and 22,921(55.5%) in 2021. Of the positive sample 29,954(72.6%) were from females and 11,326(27.4%) from males, and 10,283(26.2%) from those aged 41-60 years, followed by 9124(22%) from those aged 61-80 years (Table 1).

Gram-positive isolates included *Enterococcus* (2020: 3,286[73%], 2021: 4,722[73%]), *Streptococcus* group D (2020: 481[11%] 2021: 635[10%]), *Streptococcus* species (2020: 381[8%] 2021: 584[9%]), *S. aureus* (2020: 180[4%]

**Table-1:** Mean organ weights (g) and ventricle thicknesses (cm) of the study population.


Number of Isolates Gender wise age groups (Year)	Year 2020		Year 2021	
	Male (n, %)	Female (n, %)	Male (n, %)	Female (n, %)
0-20	998 (35%)	1648 (65%)	882(26%)	2555 (74%)
20-40	861 (15%)	5273 (85%)	1217 (17%)	5777 (83%)
41-60	1297 (27%)	3409 (73%)	1776 (30%)	4341 (70%)
61-80	1709 (40%)	2572 (60%)	1940(41%)	2903 (59%)
>80	268 (45%)	324 (55%)	378 (25%)	1152 (75%)
Total	5133 (28%)	13226 (72%)	6193 (27%)	16728 (73%)

2021: 236[3.6%]), coagulase-negative staphylococcus species (2020: 173[3.8%, 2021: 240[3.7%]) and *S. saprophyticus* (2020: 28[0.6%, 2021: 23[0.3%]). Gram-negative lactose fermenters comprised *E. coli* (2020: 10,873[86%, 2021: 12,250[82%]), *K. pneumoniae* (2020: 1,226[9.7%, 2021: 1,767 [11.8%]), enterobacter species (2020: 233[2%, 2021: 565[4%]), klebsiella species (2020: 188[1%, 2021: 36[0.2%]), *K. oxytoca* (2020: 20[0.15%, 2021: 222[1.49%]), citrobacter species (2020: 12[0.09%, 2021: 12[0.80%]), citrobacter freundii (2020: 7[0.03%, 2021: 1[0.006%] and citrobacter koseri (2020: 0[0%, 2021: 1[0.006%]). Non-lactose fermenters numbered 1,271 in

**Table-2:** Antibiotic resistance pattern of uro-pathogens.

	Pseudomonas aeruginosa		Pseudomonas spp		Acinetobacter spp		Proteus mirabilis		Proteus vulgaris		Morganella morganii		Providencia spp		Sternophomasm altophila		Aeromonas spp	
	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021	2020	2021
<b>Anti biotics</b>	(n=498)	(n=612)	(n=30)	(n=35)	(n=332)	(n=465)	(n=185)	(n=190)	(n=44)	(n=39)	(n=88)	(n=82)	(n=6)	(n=4)	(n=10)	(n=17)	(n=14)	(n=32)
<b>AMK</b>	93 (19%)	131 (21.4%)	3 (10%)	10 (28%)	32 (9.6%)	69 (15%)	7 (3.7%)	21 (11%)	2 (4.5%)	3 (7.6%)	7 (7.9%)	8 (9.7%)	2 (33%)	1 (33.3%)	NT	NT	NT	NT
<b>CN</b>	135 (27.23%)	153 (25%)	4 (15%)	10 (28%)	65 (19.57%)	93 (20%)	35 (18.9%)	57 (30%)	15 (34%)	17 (43.5%)	29 (32.9%)	22 (26.8%)	2 (33%)	2 (50%)	NT	NT	NT	NT
<b>AMP</b>	NT	NT	NT	NT	NT	NT	112 (60%)	143 (75%)	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
<b>AMC</b>	NT	NT	NT	NT	NT	NT	60 (32.4%)	82 (43%)	27 (61.3%)	31 (89.4%)	NT	NT	NT	NT	NT	NT	7 (50%)	24 (75%)
<b>TZP</b>	60 (12%)	86 (14%)	2 (6.6%)	6 (17%)	40 (12.12%)	92 (20%)	7 (3.7%)	7 (3.7%)	2 (5.0%)	5 (12.8%)	5 (5.6%)	5 (6%)	0 (0%)	0 (0%)	NT	NT	2 (14.2%)	5 (15.6%)
<b>CFM</b>	NT	NT	NT	NT	NT	NT	105 (56.7%)	116 (61%)	42 (95%)	36 (92.3%)	81 (92%)	63 (76.8%)	3 (50%)	2 (50%)	NT	NT	0 (0%)	16 (50%)
<b>CAZ</b>	115 (23%)	159 (26%)	2 (7.6%)	7 (20%)	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	2 (20%)	6 (35%)	NT	NT
<b>CRO</b>	NT	NT	NT	NT	196 (59%)	299 (64%)	76 (41%)	83 (43%)	32 (72.7%)	27 (69.2%)	50 (56.8%)	40 (48.7%)	2 (33%)	2 (50%)	NT	NT	2 (14.2%)	6 (18%)
<b>CXM</b>	NT	NT	NT	NT	NT	NT	107 (57.8%)	117 (61%)	NT	NT	NT	NT	2 (33%)	3 (75%)	NT	NT	4 (28.5%)	19 (59.3%)
<b>MEM</b>	254 (51%)	263 (43%)	10 (33%)	8 (22%)	54 (16.2%)	95 (20.4%)	5 (2.7%)	5 (2.6%)	0 (0%)	2 (5.1%)	6 (6.8%)	7 (8.5%)	0 (0%)	0 (0%)	NT	NT	0 (0%)	1 (0.09%)
<b>LEV</b>	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	1 (10%)	1 (5.8%)	0 (0%)	2 (6.25%)
<b>CIP</b>	137 (28%)	181 (30%)	7 (23%)	14 (40%)	98 (30%)	137 (30%)	57 (30.8%)	79 (42%)	29 (66%)	26 (66.6%)	57 (64.7%)	52 (63.4%)	2 (33%)	3 (75%)	NT	NT	0 (0%)	4 (12.5%)
<b>SXT</b>	NT	NT	NT	NT	130 (39%)	166 (35.6%)	146 (79%)	143 (75.2%)	29 (66%)	28 (74%)	58 (66%)	48 (59%)	2 (33%)	2 (50%)	2 (20%)	4 (23.5%)	0 (0%)	8 (25%)
<b>TOB</b>	403 (81%)	477 (78%)	23 (76%)	35 (100%)	226 (68%)	350 (75.2%)	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT

AMK: Amikacin, CN: Gentamicin, AMP: Ampicillin, AMC: Amoxicillin / Clavulanic acid, TZP: Piperacillin-tazobactam, CFM: Cefixime, CAZ: Ceftazidime, CRO: Ceftriaxone, CXM: Cefuroxime, MEM: Meropenem, LEV: Levofloxacin, CIP: Ciprofloxacin, SXT: Co-trimoxazole. TOB: Tobramycin, NA: Not applicable NT: Not tested.



**Figure:** Frequency of various species of non-lactose fermenting gram-negative uro-pathogens.

2020 and 1,627(%) in 2021 (Figure). Among them, *Pseudomonas (P.) aeruginosa* (2020: 498[3%], 2021: 612[3%]) was the most prevalent organism. followed by *acinetobacter* (2020: 332[26%], 2021: 465[29%]), *proteus mirabilis* (2020: 185[15%], 2021: 190[12%]), *morganella morganii* (2020: 88[7%], 2021: 82[5%]) and *proteus vulgaris* (2020: 44[3%], 2021: 39[2.3%]).

*P. aeruginosa* was most resistant against TOB 880(79.3%) and least resistant against TZP 146(13%). Comparison of antibiotic susceptibility pattern of 2020 and 2021 was noted in detail (Table 2).

## Discussion

UTI is the most prevalent infection affecting people worldwide, and is rated as the third most common infectious disease. Uncomplicated UTIs are cured with short courses of antibiotics, but urine samples are sent in several cases for microbiological assessment following treatment failure or chronic or worsening infection.<sup>14</sup> The most consistently associated infectious agents of UTIs are enterobacterales, including *E. coli* and *klebsiella*, *citrobacter*, *enterobacter*, *serratia*, *proteus*, *morganella* and *providencia* species, gram-positive cocci, including *enterococcus* species, *S. aureus* and *S. saprophyticus*, and NLF-GNBs, like *P. aeruginosa*.<sup>11</sup>

The current study had 41,280 urine samples positive for bacterial growth. Females of reproductive age formed the primary group of patients with UTI, which was in line with literature that has extensively reported that women have a greater occurrence of UTIs than males, primarily due to anatomic and physical issues.<sup>15</sup> Similarly, a study documented that elderly woman aged >61 showed lower UTI incidence (22%) than males. This was perhaps because with age, males develop prostate swelling and neurogenic bladder.<sup>16</sup>

In the present study, among gram-negative uro-pathogens, *E. coli* had the highest prevalence, followed

by *K. pneumonia*, which has been reported earlier as well.<sup>10,17</sup> The enterococci species was the dominant pathogen compared to other gram-positive isolates, having a slightly higher prevalence than a study in 2016.<sup>18</sup> NLF-GNBs are frequently correlated with uro-pathogenicity.<sup>19</sup> Among NLF-GNBs, most of the urine infections were caused by *P. aeruginosa* and *acinetobacter* species, which is similar to the data reported earlier.<sup>20</sup> These two isolates showed increased resistance pattern against AMK, TZP, CAZ and CIP. However *P. aeruginosa* was found to be more resistant towards MEM and TOB., *Acinetobacter* isolates were resistant against CRO. The findings closely resembled those reported earlier.<sup>21</sup> However, contradictory findings have also been reported.<sup>22</sup> In the present study, *proteus mirabilis* and *proteus vulgaris* showed resistance against several antibiotics, but higher resistance was observed with CFM and CRO. This was in line with another study.<sup>23</sup>

LF-GNBs represent a challenge to clinicians because of their rising resistance against various antibiotics classes, ultimately leading to multidrug resistance (MDR), extensive drug-resistance (XDR), or even pan-drug resistance (PDR).<sup>24</sup> The resistance in these clinical isolates has developed owing to various mechanisms, such as intrinsic non-susceptibility processes, alterations or through plasmids/integrations during the extended course of therapy although the same treatment was effective primarily. The resistance mechanism contains porin deficiency and mutations impacting outer membrane absorbency ( $\beta$ -lactam antibiotics), changes in target locations (aminoglycosides, fluoroquinolones), energy-reliant efflux pumps (fluoroquinolones), as well as the making of drug-inactivating enzymes.<sup>25</sup>

The current study has limitations as it did not deal with UTI prevalence in the local population. Besides, the current data could not correlate antimicrobial resistance with the duration and cause of UTI because it was retrieved from the laboratory records in which clinical data is not recorded.

## Conclusion

Among NLF-GNBs, *P. aeruginosa* and *acinetobacter* species were the most frequent cause of uro-pathogenicity, with great resistance towards MEM, TOB, AMK, TZP, CAZ and CIP. There is an urgent need for antibiotic stewardship and infection control measures in healthcare settings.

**Acknowledgement:** We are grateful to all those who facilitated the data-collection process.

**Disclaimer:** None.

**Conflict of Interest:** None.

**Source of Funding:** None.

## References

- Brejijeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. *Molecules*. 2020;25:1340. doi: 10.3390/molecules25061340.
- Bazaid AS, Saeed A, Alrashidi A, Alrashidi A, Alshaghдали K, A Hammam S, et al. Antimicrobial surveillance for bacterial uropathogens in Ha'il, Saudi Arabia: A Five-year multicenter retrospective study. *Infect Drug Resist*. 2021;14:55-65. doi: 10.2147/IDR.S299846. eCollection 2021.
- Joanna L. Langner, Kim F. Chiang, Randall S. Stafford, Current prescribing practices and guideline concordance for the treatment of uncomplicated urinary tract infections in women. *Am J Obstet Gynecol* 2021;225:272. <https://doi.org/10.1016/j.ajog.2021.04.218>.
- Öztürk, R., Murt, A. Epidemiology of urological infections: a global burden. *World J Urol* 2020;38: 2669–79. <https://doi.org/10.1007/s00345-019-03071-4>.
- Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Yamada K, et al. Correlation between Antimicrobial Resistance and the Hospital-Wide Diverse Use of Broad-Spectrum Antibiotics by the Antimicrobial Stewardship Program in Japan. *Pharmaceutics* 2023;15:518. <https://doi.org/10.3390/pharmaceutics15020518>
- Kariuki WK, Nyerere KS, Apondi OJ. Antimicrobial Susceptibility Patterns of *Escherichia coli* Isolated from Olive Baboon (*Papio anubis*) Gut. *Am J Infect Dis*. 2018;6:38-45.
- Ghazal L, Qureshi AH, Iqbal N. Antibiotic Susceptibility Pattern of Gram Negative Bacilli Isolated from Different Clinical Specimens in a Tertiary Care Hospital. *J Islamabad Med Dental Coll*. 2018;7:112-7.
- Molewa ML, Barnard T, Naicker N. A potential role of cockroaches in the transmission of pathogenic bacteria with antibiotic resistance: A scoping review. *The J Infect Dev Ctries*. 2022;16:1671-78. doi: 10.3855/jidc.16893.
- Muhwezi I, Bazira J, Zamarano H, Byarugaba F, Sabiiti W, Holden M, et al. Quantification and Molecular Characterization of Extended Spectrum Beta-Lactamase Producing Enterobacteriaceae from Agropastoral Communities of Mbarara District, South Western Uganda. *Systemat Rev Pharmacy*. 2022;13:830-40. <https://doi.org/10.21203/rs.3.rs-1673469/v1>
- Gajdács M, Burián K, Terhes G. Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. *Antibiotics*. 2019;8:143. doi: 10.3390/antibiotics8030143.
- Gajdács M, Ábrók M, Lázár A, Burián K. Differential epidemiology and antibiotic resistance of lactose-fermenting and non-fermenting *Escherichia coli*: Is it just a matter of taste? *Biologia Futura*. 2020;71:175-82.
- Standards NcfcL. Performance standards for antimicrobial disk susceptibility tests: approved standards: National Committee for clinical laboratory standards; 2006.
- Weinstein MP PJ, Campeau S, Eliopoulos GM, GalaS FM, Humphries RM, et al Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing. 33 ed 2023.
- Kothari A, Kumar S, Omar BJ, Kiran K. Detection of extended-spectrum beta-lactamase (ESBL) production by disc diffusion method among *Pseudomonas* species from various clinical samples. *J Fam Med Primary care*. 2020;9:683.
- Algammal AM, Hashem HR, Alfifi KJ, Hetta HF, Sheraba NS, Ramadan H, et al. atp D gene sequencing, multidrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR-*Proteus mirabilis*. *Scientific reports*. 2021;11:9476. <https://doi.org/10.1186/s13568-023-01615-x>
- Eldeeb H, Serry F, Ghoname N, Abbas H. In vitro activity of tigecycline against local clinical isolates of some Enterobacteriaceae. *Zagazig J Pharmaceutical Sci*. 2020;29:9-20.
- Ahmed K, Raja I, Hussain I, Jan M, Nafees M, Jahan Z, et al. Prevalence of *Escherichia coli* in suspected urinary tract infected patients and their sensitivity pattern against various *Escherichia coli* in suspected urinary tract infected patients and their sensitivity pattern against various antibiotics in Gilgit-Baltistan, Pakistan. *Pak J Zool*. 2014;46:1783-8.
- Hussain A, Sohail M, Abbas Z. Prevalence of *Enterococcus faecalis* mediated UTI and its current antimicrobial susceptibility pattern in Lahore, Pakistan. *J Pak Med Assoc*. 2016;66:1232.
- Bajpai T, Pandey M, Varma M, Bhatamare G. Importance of identification of lactose nonfermenting *Escherichia coli* and their prevalence in urinary isolates. *CHRISMED J Health Res*. 2016;3:288. DOI:10.4103/2348-3334.190581
- Al Hag WA, Elbadawi H, Hamid MMA. Use of 16s rRNA to identify non-lactose-fermenting bacilli and molecular detection of ESBL resistance genes associated with hospital-acquired infection in Soba University Hospital, Sudan. *F1000Research*. 2020;9:1311.
- Rasool MS, Siddiqui F, Ajaz M, Rasool SA. Prevalence and antibiotic resistance profiles of Gram negative bacilli associated with urinary tract infections (UTIs) in Karachi, Pakistan. *Pak J Pharm Sci*. 2019;32:2617-23.
- Olowo-Okere A, Ibrahim YKE, Nabti LZ, Olayinka BO. High prevalence of multidrug-resistant Gram-negative bacterial infections in Northwest Nigeria. *Germs*. 2020;10:310-21. doi: 10.18683/germs.2020.1223. eCollection 2020 Dec.
- Kwon J, Yang M-H, Ko H-J, Kim S-G, Park C, Park S-C. Antimicrobial resistance and virulence factors of *Proteus mirabilis* isolated from Dog with chronic otitis externa. *Pathogens*. 2022;11:1215. 10.3390/pathogens11101215.
- Ibrahim HK. Screening and sensitivity of non-lactose fermenting bacteria to antibiotics by Vitek-2 compact system. *University of Thi-Qar Journal of Science*. 2019;7(1):79-83. DOI:10.32792/utq/utjsoci/vol7/1/14
- Bhaskar B, Sumitha R. Isolation and Identification of Pathogenic Microorganisms associated with Electronic Devices from Healthcare Professionals in and around Chennai; 2022.

## Author's Contributions

**AF:** Conception, synthesis, planning of research, active participation in methodology, interpretation, analysis critical review, final approval.

**MR:** Introduction, discussion, review of literature, referencing.

**MS:** Data collection, interpretation, analysis.

**HG:** Data Interpretation, analysis, critical review.

**WI:** Data collection, active participation in methodology.

**RB:** Introduction, referencing, critical review.